Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.
OBJECTIVE:To measure Met protein content in prostate biopsies guided by fused magnetic resonance and ultrasound imaging, and to measure soluble Met (sMet) protein concentration in plasma samples from patients presenting evidence of prostate cancer. PATIENTS AND METHODS:345 patients had plasma sample...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4907470?pdf=render |
| _version_ | 1828398542646935552 |
|---|---|
| author | Deborah R Kaye Peter A Pinto Fabiola Cecchi Joseph Reilly Alice Semerjian Daniel C Rabe Gopal Gupta Peter L Choyke Donald P Bottaro |
| author_facet | Deborah R Kaye Peter A Pinto Fabiola Cecchi Joseph Reilly Alice Semerjian Daniel C Rabe Gopal Gupta Peter L Choyke Donald P Bottaro |
| author_sort | Deborah R Kaye |
| collection | DOAJ |
| description | OBJECTIVE:To measure Met protein content in prostate biopsies guided by fused magnetic resonance and ultrasound imaging, and to measure soluble Met (sMet) protein concentration in plasma samples from patients presenting evidence of prostate cancer. PATIENTS AND METHODS:345 patients had plasma samples drawn prior to image-guided biopsy of the prostate. Of these, 32% had benign biopsies. Of the 236 that were positive for prostate adenocarcinoma (PCa), 132 treated by total prostatectomy had Gleason scores of 6 (17%), 7, (55%), 8 (16%), or 9-10 (12%). 23% had evidence of local invasion. Plasma samples were also obtained from 80 healthy volunteers. Tissue Met and plasma sMet were measured by two-site immunoassay; values were compared among clinically defined groups using non-parametric statistical tests to determine significant differences or correlations. RESULTS:PCa tumor Met correlated significantly with plasma sMet, but median values were similar among benign and malignant groups. Median plasma sMet values were also similar among those groups, although both medians were significantly above normal. Median Met content in primary PCa tumors and sMet concentrations were independent of Gleason score, final pathologic stage and age. CONCLUSION:Plasma sMet is not predictive of PCa or its severity in patients with organ-confined or locally invasive disease. Quantitative analysis of Met protein content and activation state in PCa tumor biopsy samples was highly feasible and may have value in follow-up to genomic and/or transcriptomic-based screens that show evidence of oncogenically relevant MET gene features that occur at relatively low frequency in non-metastatic PCa. |
| first_indexed | 2024-12-10T09:04:02Z |
| format | Article |
| id | doaj.art-4e639ba113d6431dbbeb804a17b23f21 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T09:04:02Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-4e639ba113d6431dbbeb804a17b23f212022-12-22T01:55:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01116e015713010.1371/journal.pone.0157130Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.Deborah R KayePeter A PintoFabiola CecchiJoseph ReillyAlice SemerjianDaniel C RabeGopal GuptaPeter L ChoykeDonald P BottaroOBJECTIVE:To measure Met protein content in prostate biopsies guided by fused magnetic resonance and ultrasound imaging, and to measure soluble Met (sMet) protein concentration in plasma samples from patients presenting evidence of prostate cancer. PATIENTS AND METHODS:345 patients had plasma samples drawn prior to image-guided biopsy of the prostate. Of these, 32% had benign biopsies. Of the 236 that were positive for prostate adenocarcinoma (PCa), 132 treated by total prostatectomy had Gleason scores of 6 (17%), 7, (55%), 8 (16%), or 9-10 (12%). 23% had evidence of local invasion. Plasma samples were also obtained from 80 healthy volunteers. Tissue Met and plasma sMet were measured by two-site immunoassay; values were compared among clinically defined groups using non-parametric statistical tests to determine significant differences or correlations. RESULTS:PCa tumor Met correlated significantly with plasma sMet, but median values were similar among benign and malignant groups. Median plasma sMet values were also similar among those groups, although both medians were significantly above normal. Median Met content in primary PCa tumors and sMet concentrations were independent of Gleason score, final pathologic stage and age. CONCLUSION:Plasma sMet is not predictive of PCa or its severity in patients with organ-confined or locally invasive disease. Quantitative analysis of Met protein content and activation state in PCa tumor biopsy samples was highly feasible and may have value in follow-up to genomic and/or transcriptomic-based screens that show evidence of oncogenically relevant MET gene features that occur at relatively low frequency in non-metastatic PCa.http://europepmc.org/articles/PMC4907470?pdf=render |
| spellingShingle | Deborah R Kaye Peter A Pinto Fabiola Cecchi Joseph Reilly Alice Semerjian Daniel C Rabe Gopal Gupta Peter L Choyke Donald P Bottaro Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. PLoS ONE |
| title | Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. |
| title_full | Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. |
| title_fullStr | Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. |
| title_full_unstemmed | Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. |
| title_short | Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. |
| title_sort | tumor and plasma met levels in non metastatic prostate cancer |
| url | http://europepmc.org/articles/PMC4907470?pdf=render |
| work_keys_str_mv | AT deborahrkaye tumorandplasmametlevelsinnonmetastaticprostatecancer AT peterapinto tumorandplasmametlevelsinnonmetastaticprostatecancer AT fabiolacecchi tumorandplasmametlevelsinnonmetastaticprostatecancer AT josephreilly tumorandplasmametlevelsinnonmetastaticprostatecancer AT alicesemerjian tumorandplasmametlevelsinnonmetastaticprostatecancer AT danielcrabe tumorandplasmametlevelsinnonmetastaticprostatecancer AT gopalgupta tumorandplasmametlevelsinnonmetastaticprostatecancer AT peterlchoyke tumorandplasmametlevelsinnonmetastaticprostatecancer AT donaldpbottaro tumorandplasmametlevelsinnonmetastaticprostatecancer |